FIELD: genetic engineering, medicine, proteins, pharmacy. SUBSTANCE: invention relates to a novel polypeptide that inhibits binding TGF-alpha (growth factor of T-cells) with its receptors. Amino acid sequence of said polypeptide is given in description. Urine is adsorbed on kaolin at acid pH value, extracted with ammonia, obtained fractions are eluted on resin Bio Rex 70 using ammonia. Obtained after elution fractions are eluted on DEAE-Sepharose resin using acetate buffer, then on CM-Sepharose using acetate buffer, then on resin HPLC C-18 using a mixture of acetate buffer with acetonitrile, then elution is carried out on resin DE-52 using acetate buffer, then on resin D-Zephyr using acetate buffer, then on resin HPLC C-18 using a mixture of an aqueous trichloroacetic acid and acetonitrile and then on resin D-Zephyr using acetate buffer that results to preparing polypeptide or polypeptide-containing pure protein. Polypeptide is encoded by DNA nucleotide sequence given in the claim of invention. Expressing vector involves DNA fragment encoding polypeptide. Strain E.coli is transformed with expressing vector and produces polypeptide with amino acid sequence given in description. Polypeptide is produced also by culturing procaryotic or eucaryotic cells transformed with expressing vector and by its isolation from cultural medium. Pharmaceutical composition that is able to inhibit binding TGF-alpha has therapeutically acceptable amount of polypeptide or pure protein in combination with one or some therapeutically acceptable filling agents or vehicles. Medicinal agent eliciting anti-inflammatory and/or anticoagulating and/or antitumor activity has polypeptide with amino acid sequence given in the claim. Invention ensures to produce a novel protein with relatively low molecular mass that can be used in preparing anti-inflammatory, anticoagulating agents for treatment and agents eliciting antitumor activity also. EFFECT: improved method of producing, valuable medicinal properties of polypeptide. 20 cl, 8 dwg, 4 ex
